Investigational Treatment for ADPKD Earns FDA’s Orphan Drug Designation
source: pixabay.com

Investigational Treatment for ADPKD Earns FDA’s Orphan Drug Designation

Approximately 540,000 individuals in the United States have been diagnosed with autosomal dominant polycystic kidney disease (ADPKD). The disease causes persistent and rapidly accumulating cysts to grow in the patient’s…

Continue Reading Investigational Treatment for ADPKD Earns FDA’s Orphan Drug Designation
Rare Community Profiles: PKD Foundation and IQVIA Partner to Create Next-Gen ADPKD Registry
source: unsplash.com

Rare Community Profiles: PKD Foundation and IQVIA Partner to Create Next-Gen ADPKD Registry

Rare Community Profiles   Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families,…

Continue Reading Rare Community Profiles: PKD Foundation and IQVIA Partner to Create Next-Gen ADPKD Registry
Developing Novel Solutions for ADPKD: An Interview with XORTX Therapeutics’ CEO Dr. Allen Davidoff
Source: Pixabay.com

Developing Novel Solutions for ADPKD: An Interview with XORTX Therapeutics’ CEO Dr. Allen Davidoff

There are limited therapeutic options for people living with autosomal dominant polycystic kidney disease (ADPKD); currently, the only real standards-of-care include dialysis and kidney transplantation. When discussing the therapeutic landscape,…

Continue Reading Developing Novel Solutions for ADPKD: An Interview with XORTX Therapeutics’ CEO Dr. Allen Davidoff
How to be a Patient Peer: Providing Resources for People with ADPKD
source: shutterstock.com

How to be a Patient Peer: Providing Resources for People with ADPKD

Acknowledgment: This story is sponsored by Otsuka America Pharmaceutical, Inc. and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing…

Continue Reading How to be a Patient Peer: Providing Resources for People with ADPKD
Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings
source: pixabay.com

Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings

According to a story from GlobeNewswire, the biopharmaceutical company Reata Pharmaceuticals, Inc., recently announced that year two of its phase 3 clinical trial has been completed. This trial is testing…

Continue Reading Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings
RGLS4326 Granted Orphan Drug Designation for Treatment of ADPKD
Photo by Robina Weermeijer on Unsplash

RGLS4326 Granted Orphan Drug Designation for Treatment of ADPKD

  In a recent press release, biopharmaceutical company Regulus Therapeutics, Inc. announced that their drug candidate, RGLS4326, received Orphan Drug Designation for the treatment of autosomal dominant polycystic kidney disease…

Continue Reading RGLS4326 Granted Orphan Drug Designation for Treatment of ADPKD
A Polycystic Kidney Disease Patient’s Advertisement for a Kidney Donor Finds a Surprising Match
source: pixabay.com

A Polycystic Kidney Disease Patient’s Advertisement for a Kidney Donor Finds a Surprising Match

  By Rachel Whetstone from In The Cloud Copy Shelly Wheaton began a car sign campaign in September to look for a live kidney donor. She was on dialysis because…

Continue Reading A Polycystic Kidney Disease Patient’s Advertisement for a Kidney Donor Finds a Surprising Match
First Patient Enrolled in Phase 3 Trial for Autosomal Dominant Polycystic Kidney Disease
Free-Photos / Pixabay

First Patient Enrolled in Phase 3 Trial for Autosomal Dominant Polycystic Kidney Disease

Do you have ADPKD? If you or someone you know has ADPKD, email us at [email protected]. We'd love to hear from you about your experience! According to a story from…

Continue Reading First Patient Enrolled in Phase 3 Trial for Autosomal Dominant Polycystic Kidney Disease
ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation
TeroVesalainen / Pixabay

ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation

According to a story from thenewsreports.com, the biopharmaceutical company XORTX Therapeutics, Inc., recently announced that the company and its partner Cato Clinical Research have received correspondence from the US Food…

Continue Reading ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation